[1] HOFMANN A F.The syndrome of ileal disease and the broken enterohepatic circulation:cholerheic enteropathy[J].Gastroenterolog,1967,52(4):752-757.
[2] WESTERGAARD H.Bile acid malabsorption[J].Curr Treat Options Gastroenterol,2007,10(1):28-33.
[3] JACKSON A,LALJI A,KABIR M,et al.The efficacy of a low-fat diet to manage the symptoms of bile acid malabsorption——outcomes in patients previously treated for cancer[J].Clin Med(Lond),2017,17(5):412-418.
[4] SCALDAFERRI F,PIZZOFERRATO M,PONZIANI F R,et al.Use and indications of cholestyramine and bile acid sequestrants[J].Intern Emerg Med,2013,8(3):205-210.
[5] WALTERS J R,PATTNI S S.Managing bile acid diarrhoea[J].Therap Adv Gastroenterol,2010,3(6):349-357.
[6] WILCOX C,TURNER J,GREEN J.Systematic review:the management of chronic diarrhoea due to bile acid malabsorption[J].Aliment Pharmacol Ther,2014,39(9):923-939.
[7] VIJAYVARGIYA P,CAMILLERI M,SHIN A,et al.Methods for diagnosis of bile acid malabsorption in clinical practice[J].Clin Gastroenterol Hepatol,2013,11(10):1232-1239.
[8] VALENTIN N,CAMILLERI M,ALTAYAR O,et al.Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea:a systematic review and meta-analysis[J].Gut,2016,65(12):1951.
[9] STERNE J A,HERNÁN M A,REEVES B C,et al.ROBINS-I:a tool for assessing risk of bias in non-randomised studies of interventions[J].Brit Med J,2016,355:i4919.
[10] WEDLAKE L,THOMAS K,LALJI A,et al.Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer:a retrospective chart review and patient questionnaire[J].Clin Ther,2009,31(11):2549-2558.
[11] BEIGEL F,TEICH N,HOWALDT S,et al.Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease:a randomized,double-blind,placebo-controlled study[J].J Crohns Colitis,2014,8(11):1471-1479.
[12] OREKOYA O,MCLAUGHLIN J,LEITAO E,et al.Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy[J].Clin Med(Lond),2015,15(3):252-257.
[13] VIJAYVARGIYA P,DONATO L J,SZARKA L A,et al.Randomized,double-blind,placebo-controlled trial of colesevelam in patients with bile acid diarrhea:effects on fecal bile acids,colonic transit,and bowel functions[J].Gastroenterology,2019,156(6):S464-S465.
[14] DEVARAKONDA A,ARNOTT I,SATSANGI J.The efficacy of colesevelam to treat bile acid malabsorption in Crohn's disease:data from TOPPIC trial[J].J Crohns Colitis,2019,13(Suppl 1):S470-S471.
[15] DAMSGAARD B,DALBY H R,KROGH K,et al.Long-term effect of medical treatment of diarrhoea in 377 patients with SeHCAT scan diagnosed bile acid malabsorption from 2003 to 2016;a retrospective study[J].Aliment Pharmacol Ther,2018,47(7):951-957.
[16] SADOWSKI D C,CAMILLERI M,CHEY W D,et al.Canadian association of gastroenterology clinical practice guideline on the management of bile acid diarrhea[J].Clin Gastroenterol Hepatol,2020,18(1):24-41.
[17] BAYS H,DUJOVNE C.Colesevelam HCl:a non-systemic lipidaltering drug[J]. Expert Opin Pharmaco,2003,4(5):779-790.
[18] BARKUN A,LOVE J,GOULD M,et al.Bile acid malabsorption in chronic diarrhea:pathophysiology and treatment[J].Can J Gastroenterol,2013,27(11):653-659.
[19] SCALDAFERRI F,PIZZOFERRATO M,PONZIANI F R,et al.Use and indications of cholestyramine and bile acid sequestrants[J].Intern Emerg Med,2013,8(3):205-210.
[20] STEINMETZ K L,SCHONDER K S.Colesevelam:potential uses for the newest bile resin[J].Cardiovasc Drug Rev,2005,23(1):15-30.
[21] RIEMSMA R,AL M,RAMOS I C,et al.SeHCAT[tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss:a systematic review and cost-effectiveness analysis[J].Health Technol Assess,2013,17(61):1-236.
[22] RUIZ-CAMPOS L,GISBERT J P,YSAMAT M,et al.Systematic review with meta-analysis:the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy[J].Aliment Pharmacol Ther,2019,49(3):242-250. |